Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

The complement cascade in Alzheimer's disease.

K R Brunden¹, W C Benzing

¹Gliatech Inc., Cleveland, Ohio 44122, USA.

Drug News & Perspectives

|December 24, 2004

Summary

Alzheimer's disease (AD) involves activated glial cells releasing complement proteins that may damage brain tissue. Therapies could target these proteins to slow AD progression without harming the immune system.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.

Current topics in medicinal chemistry·2011

Same author

Aβ-Induced Proinflammatory Cytokine Release from Differentiated Human THP-1 Monocytes.

Methods in molecular medicine·2011

Same author

Generation of cell lines for drug discovery through random activation of gene expression: application to the human histamine H3 receptor.

Assay and drug development technologies·2005

Same author

Inhibition of complement alternative pathway function with anti-properdin monoclonal antibodies.

Molecular immunology·2000

Same author

Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia.

Journal of neurochemistry·2000

Same author

Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice.

Neurobiology of aging·2000

Area of Science:

Neuroscience
Immunology
Pathology

Background:

Activated glial cells in Alzheimer's disease (AD) release molecules contributing to pathology.
Complement proteins are key players, known for inflammation and potential host tissue damage.

Purpose of the Study:

To strengthen the hypothesis that complement activation contributes to AD neuropathology.
To identify potential therapeutic agents to attenuate complement activity in AD.

Main Methods:

Reviewing evidence on complement protein association with senile plaques in AD brain.
Investigating the role of amyloid-beta (Abeta) in activating the complement system.

Main Results:

Early complement pathway components are found with senile plaques in AD brain.
Evidence suggests Abeta activates complement, potentially through Abeta-C1q binding.

Conclusions:

Demonstrating terminal complement activation products in AD brain is crucial for understanding disease mechanisms.
Developing drugs to modulate complement activity in AD is a promising therapeutic avenue.

Related Experiment Videos